All News
Check out MothertoBaby fact sheets by the NIH and LactRX (by mother to baby) app for pregnancy, disease, and medications. Dr. C. Chambers highlighted this today at #RNL2023 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
#RNL2023 Year in Review
Male response better than female response in patients with PsA in SELECT-PsA evaluating UPA/ADA.
More targeted studies needed
@RheumNow https://t.co/Z3kbM0e9A0
Eric Dein ericdeinmd ( View Tweet)
#RNL2023 Year in Review
BE COMPLETE: P3 trial Bimekizumab for PsA in TNF inadequate responses at 16 weeks
160 mg BKZ SQ q4w vs PBO
ACR50 43%, PBO 7%
PASI 1000: BKZ 58.5% vs PBO 4.5%
Safety: oral candidiasis: 2.6% BKZ vs PBO 0%
@RheumNow https://t.co/bW00Wg6Cnf
Eric Dein ericdeinmd ( View Tweet)
Talk to me about candidiasis. BKZ showed increased safety signals for candida infections. I fear infxns may be under reported (after approval and in use) if patients see other physicians for treatment vs their rheumatologist/derm. Thoughts on this signal? #RNL2023 @rheumnow https://t.co/UPA5oP9G49
Dr. Rachel Tate uptoTate ( View Tweet)
TYK2 in plaque psoriasis By Eric Ruderman #RNL2023 @RheumNow
Safer?
No lab monitoring
And it works https://t.co/9Woen2q4hZ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
TYK2 signalling Vs JAK signalling summary
#RNL2023 https://t.co/0VNBiEc6jq
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
Approach to pregnancy in patients with PsA , By Dr.Chambers #RNL2023 @RheumNow https://t.co/8tSz7qbmQU
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Prevalence of PsA in women of reproductive age, By Dr.Chambers #RNL2023 @RheumNow https://t.co/hB6QQtz7fw
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dr. Laura Coates on PsA treatment:
- Applying treat to target associated with better quality of life
- low disease activity is a reasonable target
Do you use PROs in managing your PsA pts? Perhaps we should
@RheumNow #RNL2023 https://t.co/36n1Cp5jtP
Robert B Chao, MD doctorRBC ( View Tweet)
Why do PROs matter? @DrLauraCoates reviewed this slide regarding the increased survival curve in end-stage cancer patients when we monitor PROs. @RheumNow #RNL2023 https://t.co/JfHNBKJGRl
Dr. Rachel Tate uptoTate ( View Tweet)
29 pts w/PsA Sine Psoriasis: 16F/13M, mean age 45 yrs w/ PsA ~6.2 yrs. 54% had 1st-degree relatives with PsA. 66% had DIP arthritis, 39% polyarticular, 36% oligoarticular, 25% were axial. Nail findings seen in 89%, enthesitis 59%, dactylitis 62% https://t.co/MlnIzGBzn0 https://t.co/8hHE3Yv8UE
Links:
Dr. John Cush RheumNow ( View Tweet)
Preterm deliveries in PsA pregnancies were more pronounced with 1- first pregnancy.
2- Discontinuation of biologic prior to pregnancy.
By Dr.Chambers #RNL2023 @RheumNow https://t.co/CxZh0ak4l0
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Neonatal outcomes:
Small for gestational age more common with an Adjusted OR off 2.42 and statistically significant.
By Dr.Chambers #RNL2023 @RheumNow https://t.co/NFMAEROEEM
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Pregnancy and #PsA
Risk of preterm delivery if
➡️first pregnancy
➡️biologic stopped pre-pregnancy
Dr Chambers at #RNL2023 https://t.co/yImZRwMuI8
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
Why JAKinibs in PsA ?! By Eric Ruderman #RNL2023 @RheumNow
Also inflammatory bowel disease and most recently Upadacitinib for crohns disease. https://t.co/loUgJNUsKT
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Jaks are every where in Psoriatic disease domains, By Eric Ruderman #RNL2023 @RheumNow
Good news, especially with Updacitinib recently and Crohn’s disease ( full package). https://t.co/nlBWJhzpLp
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
⚠️Only 12-43% of #PsA patients achieved remission or very low disease activity
From systematic review in RWE presented by @DrLauraCoates
#RNL2023
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
Treat to target approach in PsA
Systematic rev: 12-43% pts achieved target of very low disease activity or remission
Pts and docs agree: remission is primary goal, but Low disease activity is acceptable alternative
@DrLauraCoates at #RNL2023
@Rheumnow https://t.co/hA7JDR7Zyh
Eric Dein ericdeinmd ( View Tweet)
I love a good graphic. Check out @DrLauraCoates’ review of the impact of MDA in PSAID scores in PsA. #RNL2023 @RheumNow https://t.co/iQYuLQobXL
Dr. Rachel Tate uptoTate ( View Tweet)
Treat to target in PSA: What's difference in our outcome scores?
DAPSA: includes CRP
MDA: includes enthesitis, skin, function
Both metrics include Tender/Swollen jt counts, and pt pain/global
Presented by @DrLauraCoates at #RNL2023
@RheumNow https://t.co/7i5m70HGiz
Eric Dein ericdeinmd ( View Tweet)
